A single amino acid substitution in hypervariable region 5 of the envelope protein of feline immunodeficiency virus allows escape from virus neutralization. by Siebelink, C.H.J. (Kees) et al.
JOURNAL OF VIROLOGY, Apr. 1993, p. 2202-2208
0022-538XJ93/042202-07$02.00/0
Copyright © 1993, American Society for Microbiology
A Single Amino Acid Substitution in Hypervariable Region 5
of the Envelope Protein of Feline Immunodeficiency Virus
Allows Escape from Virus Neutralization
KEES H. J. SIEBELINK,1 GUUS F. RIMMELZWAAN,1 MARNIX L. BOSCH,' ROB H. MELOEN,2
AND ALBERT D. M. E. OSTERHAUSl13*
Laboratory of Immunobiology, National Institute ofPublic Health and Environmental Protection, Antonie
van Leeuwenhoeklaan 9, P.O. Box 1, 3720 BA Bilthoven, 1 Central Veterinary Institute, 8200AB Lelystad, 2
and Veterinary Faculty, Division of Virology, Institute of Infectious Diseases and Immunology,
State University of Utrecht, 3508 TD Utrecht, The Netherlands
Received 11 September 1992/Accepted 11 December 1992
We infected a specific-pathogen-free cat (cat 14) with molecularly cloned feline immunodeficiency virus clone
19kl (FIV19kl [K. H. J. Siebelink, I. Chu, G. F. Rimmelzwaan, K. Weoer, A. D. M. E. Osterhaus, and M. L.
Bosch, J. Virol. 66:1091-1097, 19921). Serum of this cat obtained 22 weeks postinfection (serum 1422)
neutralized FIV19kl but not FIV19k32, which is 99.3% identical to FIV19kl in the envelope gene. Serum 1422
also neutralized virus isolated from cat 14 at weeks 2 and 32 postinfection. We then cultured FIV19kl in the
continuous presence of serum 1422, which resulted in a delay in virus replication of 6 weeks. The resulting virus
population appeared to be resistant to virus neutralization by serum 1422. Nucleotide sequencing of the env
open reading frame of this presumed escape mutant revealed the presence of one silent and two substitution
mutations, both of the latter in hypervariable region 5. Through the construction of chimeric viruses and
site-directed mutagenesis, we demonstrated that one of these mutations, the substitution of lysine to glutamine
at amino acid position 560 in hypervariable region 5, was sufficient to allow the escape of FIV19kl from
neutralization by serum 1422.
Feline immunodeficiency virus (FIV) is a recently discov-
ered T-lymphotropic lentivirus (28) which appeared to be the
cause of an AIDS-like disease in naturally infected cats (14,
15, 28, 36, 39, 44). FIV resembles human immunodeficiency
virus type 1 (HIV-1) in its biological and morphological
properties. A decline in numbers of CD4+ lymphocytes
observed in vivo and in vitro (1, 3, 13, 37), a gradual loss of
immune function (3, 11, 18, 38, 41, 44), and the occurrence of
opportunistic infections as in human AIDS make FIV infec-
tion in cats a useful small animal model for the study of HIV
infections in humans.
Infection with lentiviruses, including FIV and HIV-1,
generally results in persistence of the virus in the host,
leading to a continuous interaction between the virus and the
immune system (4, 6, 21, 22, 24, 25, 44). Genetic variation
allows the virus to escape from the continuous pressure
exerted by antibodies (20, 32, 43; for a review, see reference
26) and cytotoxic T cells (29). Domains on the envelope
glycoprotein that induce virus neutralizing (VN) antibodies
have been determined (7, 10, 12, 17, 40), and escape from
VN antibodies has been described in various lentiviral
systems. After infection with HIV-1, two types of VN serum
antibodies are observed. Shortly after infection, type-spe-
cific neutralizing antibodies that are mainly targeted to the
principal neutralizing determinant (PND) within variable
region 3 arise (10, 27, 34). Later in the course of infection,
more broadly neutralizing antibodies in which other anti-
genic sites on the envelope protein are also involved are
induced (7, 16, 19, 31, 40; for a review, see reference 9). The
envelope gene of FIV is highly variable but exhibits, like the
envelope gene of HIV-1, constant and more variable regions
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(23, 30, 37). FIV neutralizing antibodies have been demon-
strated in the sera of infected cats (5, 42), but the sites
involved in their induction have not been identified. The
generation ofVN escape mutants and studies concerning the
mechanisms leading to escape may provide more informa-
tion about the structural and functional properties of these
antigenic sites. Two mechanisms by which a lentivirus can
escape from VN antibody pressure have been described.
The first involves changes in the binding site itself, whereas
the other involves changes elsewhere on the envelope gly-
coproteins (20, 43). The availability of molecular clones of
HIV-1 has allowed the identification of the molecular basis
underlying the escape of the virus from neutralizing antibody
and has provided evidence that both mechanisms are oper-
ational (20, 32, 43).
In an attempt to elucidate the mechanism by which FIV
would escape from VN pressure, we have used the same
approach. Thus, we have identified a single amino acid
change in the envelope glycoprotein of FIV that leads to
escape of the virus from neutralizing antibody.
MATERIALS AND METHODS
Virus. Viral progeny of replication-competent molecular
clones 19kl (FIV19kl) and 19k32 (FIV19k32) and the un-
cloned isolate FIV A'daml9 were obtained as described
previously (37). A 10-week-old specific-pathogen-free (SPF)
cat (cat 14) was infected with FIV19kl by intraperitoneal
inoculation of 102 50% tissue culture infectious doses. Virus
was reisolated from this cat at 2 and 32 weeks postinfection
(p.i.) and designated FIV19k1R2 and FIV19k1R32, respec-
tively.
Sera. Serum of a naturally FIV infected cat, A'daml9, was
designated serum A19 (37). Serum of cat 14 was taken prior
to infection (preserum) and at 22 weeks p.i. (designated
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serum 1422). Serum of a noninfected SPF cat was used as a
control serum (SPF serum). All sera were heat inactivated
for 1 h at 56°C prior to use.
Gag- and Env-specific ELISAs. The presence of antibodies
directed against the envelope protein of FIV was detected in
a recombinant FIV envelope protein enzyme-linked immu-
nosorbent assay (ELISA) as described elsewhere (33), and
antibodies raised against Gag proteins were detected in a
commercially available FIV p24/p17 antibody ELISA as
recommended by the manufacturer (European Veterinary
Laboratory, Amsterdam, The Netherlands).
RT assay. Reverse transcriptase (RT) activity was deter-
mined as previously described (37).
VN assay. Since low virus passage levels were used to
avoid additional mutations by in vitro culturing, and the
virus titer of the stocks propagated in feline peripheral blood
mononuclear cells (PBMC) (37) was low (approximately
102), we decided to standardize the viral input by RT
activity. Virus stocks of FIV19kl, FIV19k32, the uncloned
isolate FIV A'daml9, and the reisolates FIV19k1R2 and
FIV19k1R32 were tested in an RT assay. For this assay, 450
pl of diluted virus stocks containing RT activity of S x 104
cpm/ml were incubated with 50 ,ul of a serum sample for 60
min at 37°C. Concanavalin A (ConA)- and interleukin-2
(IL-2)-stimulated PBMC (106) were added. After 60 min at
37°C, the cells were washed and incubated for 14 days in CM
(RPMI 1640 [GIBCO], penicillin [100 IU/ml], streptomycin[100 ,g/ml], L-glutamine [2 mM], 3-mercaptoethanol [2 x
10-5 M], IL-2 [100 IU/ml]) supplemented with 2% of the
respective serum sample. RT activity was determined as a
measure for virus production. Virus neutralization was con-
sidered positive when the RT activity did not increase over
two times the background level defined as the mean RT
activity of uninfected cells. In previous experiments, it was
observed that the RT activity of FIV-infected cultures was at
least five times the background level (not shown).
Generation of escape mutants. ConA- and IL-2-stimulated
PBMC of an SPF cat (106) were infected with FIV19kl. After
24 h, the cultures were divided between two identical flasks.
To one of the cultures we added 2% serum 1422, and to the
other we added 2% SPF serum (control serum). The culture
supernatants were harvested weekly, replaced with fresh CM
supplemented with a 2% concentration of the respective
serum, and tested for the presence of RT activity. When RT
activity over five times background values was present, the
supernatant was filtered through a 220-nm-pore-size filter and
stored at
-135°C. Viruses derived from these cultures were
designated l9klA and l9klB when derived from cultures with
serum 1422 or with SPF serum, respectively. Dilutions of the
culture supernatants of l9klA and l9klB containing RT
activity of S x 104 cpm/ml were incubated with 10% serum
1422 or SPF serum for 60 min at 37°C. ConA and IL-2-
stimulated PBMC of an SPF cat (106) were added to each
culture. After 60 min of incubation at 37°C, the cells were
washed and cultured in CM supplemented with a 2% concen-
tration of the respective serum. The culture supernatant was
tested for the presence ofRT activity twice a week. When RT
activity could be demonstrated, the culture supematant was
filtered through a 220-nm-pore-size filter and stored at
-135°C. The viruses were designated l9klA,A and 19kLA,B
for l9klA propagated in the presence of serum 1422 and SPF
serum, respectively, and l9klB,A and l9klB,B for l9klB
propagated in the presence of serum 1422 and SPF serum,
respectively. l9klA,A was further designated l9klesc.
Sequence analysis. The sequence of the envelope gene of
19kl has been described previously (37). The envelope gene
of the escape mutant l9klesc was amplified by polymerase
chain reaction (PCR). PBMC (105) from the 19klesc culture
were pelleted and lysed with 100 ,lI ofK buffer (50 mM KCI,
10 mM Tris [pH 8.4], 1.5 mM MgCl2, 0.5% Tween 20, 100 ,ug
of proteinase K per ml) for 45 min at 56°C. The reaction was
stopped by incubating the mixture for 5 min at 95°C. Two
oligonucleotide primers were designed (primer 1, 5'-GGC
GAATTCATGGCAGAAGGAT'ITGTAGCC-3'; primer 2, 5'-
TATGCATGCTCATTCCTCCTC1TCAGACATGCC-
3') which contained EcoRI and SphI restriction enzyme
cleavage sites (underlined), respectively, to facilitate subse-
quent cloning into pUC19. PCRs were carried out in a
separate laboratory (to avoid contamination) in a volume of
100 pl containing 10 ,ul of the cell lysate, 50mM KCl, 10 mM
Tris (pH 8.4), 1.5 mM MgCl2, 0.02% gelatin, 250 ,uM
deoxynucleoside triphosphates, 1 ,uM each primer, and 2.5
U of Taq polymerase. Samples were overlaid with 100 ,ul of
mineral oil to avoid evaporation and then subjected to 35
amplification cycles consisting of a denaturing step (94°C, 1
min), a primer-annealing step (60°C, 1 min), and a primer
extension step (72°C, 2 min). Negative controls (noninfected
PBMC from an SPF cat) were amplified in parallel. Ampli-
fication products were analyzed by agarose gel electrophore-
sis (0.8%) for the presence of the appropriately sized DNA
fragments. Excess primers in the PCR were eliminated by
using a Centricon-30 microconcentrator (Amicon). DNA
was digested with EcoRI and SphI and cloned into pUC19.
The subclone was used for the dideoxynucleotide chain
termination reaction (35) of the envelope gene. The nucleotide
and protein alignments were done with Lasergene software
(DNAstar Inc., London, United Kingdom). The observed
nucleotide variation of l9klesc was confirmed by using an
independent PCR amplification to exclude Taq errors.
Generation of chimeric clones. The construction of chi-
meric clones is schematically represented in Fig. 1. Restric-
tion mapping identified a common and a unique internal SphI
site in both FIV genomes. To generate recombinant viruses,
the lambda clones 19kl and 19k32 were digested with SaIlI
and SphI. The SailI and SphI fragments generated after
digestion were cloned into plasmid vector pUC19 from
which the Kpnl site had been deleted. The plasmids contain-
ing the 5' long terminal repeat, gag, and 5' part ofpol were
designated 5' subclones. Plasmids containing the 3' part of
pol, env, and 3' long terminal repeat were designated 3'
subclones and were used to exchange internal 1,662-bp KpnI
fragments between clones 19kl and 19k32.
The 1,662-bp KpnI fragment of clone 19kl was also cloned
into pUC19 and was designated the 3'KK subclone of 19kl.
A 144-bp NsiI-MstII fragment of the l9klesc envelope (see
above) was exchanged, as was a 144-bp NsiI-MstII fragment
of clone 19kl in which one nucleotide was substituted by
site-directed mutagenesis at either position 1667 or position
1678. Site-directed mutagenesis was performed by PCR on
the 3' subclone of 19kl. To that end, three oligonucleotides
were designed. Primer 1 (5'-CCFTATTAITiCAiTTTCAA
TATGACAAAAGCTG-3') contained an NsiI site (under-
lined); primer mutl (5'-GCCTFFrFrcCTCAQG ACATTCC
AlTTllATTGTGTGAGTATTG-3') contained an MstII
site (underlined) and a T-to-G substitution at position 1667
(italic); primer mut2 (5'-GCCrTfffCCTCAQQACATTC
CAT'lTGTATTG-3') contained an MstII site (underlined)
and a T-to-G substitution at position 1678 (italic). Two PCRs
were carried out, using in both reactions primer 1 to prime
from the 5' end. In one reaction primer mutl was used while
in the other reaction primer mut2 was used to prime from the
3' end. The conditions for PCR are described above. PCR
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FIG. 1. Schematic representation of the construction of chimeric
FIV clones (see text for details). The uppermost bars represent the
major open reading frames gag, pol, and env. Restriction enzyme
cleaving sites are indicated as follows: K, IpnI; M, MstII; N, NsiI;
S, Sall; Sp, SphI. Individual point mutations are indicated (v).
fragments were digested with NsiI and MstII and cloned into
the 3'KK subclone of 19kl. The mutagenesis was confirmed
by sequence analysis.
The 1,662-bp KpnI fragments from the 3'KK subclones in
which 144-bp NsiI and MstII fragments were exchanged
were cloned into the 3' subclone of 19kl; 2.5-,ug amounts of
each of the 3' subclones and the 5' subclones were mixed,
digested with SphI, and ligated. After digestion with Sall,
the constructs were transfected into Crandell feline kidney
(CrFK) cells as previously described (37). Virus production
was rescued by cocultivation of transfected cells with ConA-
and IL-2-stimulated PBMC for 3 days. Cultures were mon-
itored for syncytium formation of PBMC and RT activity in
the culture supernatant. When RT activity could be mea-
sured, culture supernatant was filtered through an 220-nm-
pore-size filter and stored in aliquots at - 135°C.
Synthesis and reaction of peptides with sera. Twelve-mer
peptides with an overlapping sequence of 11 amino acids
were synthesized and analyzed for reactivity with sera as
previously described (8). The amino acid sequences of the
peptides were based on the amino acid sequences of the
envelope proteins of clones 19kl and l9klesc between
amino acid positions 549 and 583. Three 12-mer control
peptides with an overlapping sequence of eight amino acids
were synthesized according to the epitope between positions
596 and 616 as described by Avrameas et al. (2).
RESULTS
Infection of cats. Upon experimental infection with viral
progeny of clone 19kl, cat 14 seroconverted within 4 weeks.
The Gag- and Env-specific serum antibodies measured by
TABLE 1. Anti-FIV serum antibody response of cat 14
determined by Gag- and Env-specific ELISA and virus isolation
after infection with FIV19kl of cat 14
Antibody response
Wk Gag Virusp.i. ([°10D45)a Env (reciprocal isolation(1D43]a titer)
0 <50 <40 NDb
2 <50 40 +
4 722 640 ND
6 902 >5,120 ND
8 1,031 >5,120 ND
11 1,186 >5,120 ND
22 1,079 >5,120 ND
32 1,036 >5,120 +
a OD450, optical density at 450 nm.
b ND, not determined.
ELISA reached plateau levels within 8 weeks after infection
(Table 1). Virus was reisolated 2 and 32 weeks p.i. (Table 1).
The serum collected 22 weeks p.i. (serum 1422) and the two
virus isolates (FIV19k1R2 and FIV19k1R32, respectively)
from this cat were used in the experiments described below.
VN activity. Serum from cat 14 (serum 1422) was tested for
VN activity against FIV19kl, FIV19k32, and the uncloned
isolates FIV A'daml9, FIV19k1R2, and FIV19k1R32. SPF
serum was used as a control. The results are listed in Table
2. Virus replication as determined by RT activity was
demonstrated in all cultures in the presence of SPF serum.
Replication of virus was detected in the presence of serum
1422 in the cultures of FIV19k32 and the uncloned isolate
FIV A'daml9. However, no virus replication was detected
in the culture infected with FIV19kl and the reisolates
FIV19k1R2 and FIV19k1R32 cultured in the presence of
serum 1422, indicating complete neutralization. Serum 1422
which was absorbed with protein A-Sepharose beads to
remove antibodies (particularly immunoglobulin G) failed to
neutralize molecular clone 19kl, which indicates that serum
immunoglobulin is responsible for the observed neutralizing
activity (not shown).
Generation of escape mutants. FIV19kl-infected PBMC
from an SPF cat were cultured in the presence of serum 1422
(culture A) or SPF serum (culture B). Within 17 days, RT
activity could be measured in the supernatant of culture B.
After 44 days of culture, RT activity was detected in culture
A (Fig. 2A). RT activity increased during time of culture. No
RT activity could be demonstrated in the noninfected cul-
tures which were cultured in the presence of serum 1422 or
SPF serum for 52 days of culture (data not shown).
The supernatants of cultures A and B were collected,
filtered 52 days p.i., and designated l9klA and l9klB,
TABLE 2. Virus neutralization of an FIV isolate, molecular
clones, and FIV reisolates with serum 1422 and SPF serum
RT activity (cpm/ml) after neutralization
Virus with:
Serum 1422 SPF serum
FIV A'daml9 24,219 61,480
FIV19kl 157 12,333
FIV19k32 26,864 59,187
FIV19k1R2 82 58,442
FIV19k1R32 103 18,145
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FIG. 2. Kinetics of virus replication expressed as RT activity of
FIV19kl (A), FIV19klA (B), and FIV19klB (C) in the presence of
serum 1422 (dashed line) or SPF serum (solid line).
respectively. These culture supernatants were incubated
with serum 1422 or SPF serum. ConA- and IL-2-stimulated
PBMC from an SPF cat were added to the virus-serum
mixture and cultured further in the presence of the respec-
tive serum, serum 1422 or SPF serum. The cultures were
designated 19klA,A and l9klA,B for the cultures of l9klA
cultured in the presence of serum 1422 or SPF serum,
respectively (Fig. 2B) and l9klB,A and l9klB,B for the
cultures of l9klB cultured in the presence of serum 1422 or
SPF serum, respectively (Fig. 2C). RT activity was demon-
strated after 17 days of infection in both cultures of l9klA.
The kinetics of virus replication of l9klA,A were similar to
those of the control l9klA,B (Fig. 2B) and l9klB,B (Fig.
2C). As expected, no virus replication was observed in the
culture l9klB,A (Fig. 2C). These results show that l9klA,A
is resistant to virus neutralization by serum 1422.
Sequence analysis. Cells of culture l9klA,A further desig-
nated l9klesc were lysed, and the envelope gene of the FIV
genome, integrated in the cellular DNA, was amplified by
PCR. The PCR product was digested with EcoRI and SphI
and cloned into pUC19. The envelope gene of l9klesc was
sequenced and compared with the envelope sequences of the
parental clone 19kl and clone 19k32 (Fig. 3). At position 468
in hypervariable region 2 (HV-2), we observed a silent
transition of T to C (not shown). Two A-to-C transversions
were observed in HV-5. One at position 1667 causes an
amino acid substitution of asparagine to threonine (amino
acid position 556), whereas the other at position 1678 causes
an amino acid substitution of lysine to glutamine (amino acid
position 560). Comparison of the nucleotide sequences of the
envelope genes of clone 19kl and clone 19k32, which exhib-
ited the same phenotype as did l9klesc in a VN assay using
serum 1422, showed the presence of a T-to-G transversion at
position 1665 and a transition of C to T at position 1669,
resulting in substitutions of asparagine with lysine (amino
acid position 555) and histidine with tyrosine (amino acid
position 557), respectively (Fig. 3).
Virus neutralization of chimeric clones. Viral progeny of
the parental clone 19kl and of those in which the envelope
gene had been exchanged partially or an amino acid had been
substituted by site-directed mutagenesis and the escape
mutant l9klesc were incubated with serum 1422 or SPF
serum prior to infection of ConA- and IL-2-stimulated thy-
mocytes. The results of this experiment are similar to those
of a number of previous experiments in which the chimeric
clones were tested separately for neutralization by serum
1422. RT activity was measured 9 and 12 days p.i. RT
activity could be measured in all control cultures 9 days p.i.
and continued to increase through 12 days p.i. (Fig. 4). As
expected, FIV19kl was neutralized by serum 1422 and not
by the SPF serum (Fig. 4A). As before, FIV19k32 was not
neutralized by serum 1422 (Fig. 4B). To investigate whether
the difference in virus neutralization between the two mo-
lecular clones was caused by the differences in the surface
protein, we exchanged the 1,662-bp KjpnI fragment. The
chimeric clones were designated 19klKK32 (19kl containing
the KpnI fragment of 19k32) and 19k32KK1 (19k32 contain-
ing the KYpnI fragment 19kl). Chimeric clone 19klKK32 was
not neutralized, whereas chimeric clone 19k32KK1 was
neutralized with serum 1422 (not shown), indicating that an
epitope within the 1,662-kb KpnI fragment of the envelope
gene is involved in neutralization.
The escape mutant of FIV19kl, grown in the presence of
serum 1422, was not neutralized by this serum (Fig. 4C).
Comparison of the amino acid sequence of the envelope
protein of 19kl and the sequence of the escape mutant
showed two amino acid substitutions within HV-5. To study
whether these substitutions underlie the escape of FIV19kl
from serum 1422, we exchanged the 144-bp NsiI-MstII
fragment, containing the whole HV-5, of clone 19kl with
that of the escape mutant. This chimera, designated
l9klNMesc, was not neutralized by serum 1422 (Fig. 4D),
indicating that one or both amino acid substitutions are
involved in the escape mechanism. By site-directed muta-
genesis, the two amino acids were substituted separately.
These point-mutated clones were designated l9klmutl (po-
sition 556, Asn to Thr) and l9klmut2 (position 560, Lys to
Gln). FIV19klmutl was neutralized by serum 1422 (Fig. 4E),
whereas FIV19klmut2 could not be neutralized by serum
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1422 (Fig. 4F), indicating that the point mutation at amino
acid position 560 resulting in an amino acid substitution from
lysine to glutamine is responsible for escape of FIV19kl
from serum 1422.
To investigate whether the differences in HV-5 between
clones 19kl and 19k32 also underlie differences in neutral-
ization with serum 1422, we reciprocally exchanged the
144-bp NsiI-MstII fragment between the two clones. This
exchange, however, did not result in a change in virus
neutralization (not shown), indicating that yet another
epitope is involved.
Pepscan analysis. Twelve-mer peptides representing the
amino acid sequence of the clones 19kl and the escape
mutant l9klesc between amino acid positions 549 and 583
were analyzed for reactivity with serum 1422, serum from a
naturally FIV infected cat, A'daml9, (serum A19), and SPF
serum. As a control for the peptide scanning (pepscan)
procedure, three 12-mer peptides spanning, with an overlap
of eight amino acids, a previously described linear epitope
on the envelope protein of FIV (from amino acid positions
596 to 616) were scanned with serum 1422, serum A19, and
SPF serum. No reactivity in these sera was detected with the
HV-5 peptides, whereas serum 1422 and serum A19 did react
in the control pepscan (not shown), suggesting that no linear
B-cell epitope in the C-terminal half of HV-5 is recognized
by serum 1422 and serum A19.
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DISCUSSION
In this report, we have demonstrated that a single amino
acid substitution in the HV-5 region of the surface glyco-
protein of FIV (amino acid position 560) allows a molecular
clone of FIV to escape neutralization by the serum of a cat
infected with this clone. Pepscan analysis of the region
around amino acid 560 with and without the substitution
showed no reactivity of the peptides with sera from cats
infected with the molecular clone or with an uncloned isolate
of FIV from the same origin. This finding suggests that the
B-cell epitope involved in the escape either is dependent on
its three-dimensional configuration or is located outside the
region where the substitution took place. In the latter case,
the amino acid substitution should have altered an epitope at
a distant site. Similar studies with escape mutants of molec-
ularly cloned HIV-1 have shown that an amino acid substi-
tution in the PND may directly result in the escape from
neutralization by a PND-specific monoclonal antibody (20).
Others have shown that an amino acid substitution in the
transmembrane glycoprotein of HIV-1 induced resistance to
neutralization by sera from seropositive individuals (32). The
basis for this resistance was shown to be most likely a
conformational change altering a neutralization-inducing de-
terminant at a distant site (43). To elucidate the mechanism
involved in the escape from neutralization observed in the
FIV system, further studies identifying antigenic sites that
induce virus neutralization will be necessary.
Our data, which showed that an FIV escape mutant could
readily be generated in the presence of VN serum antibody,
suggest the predominance of type-specific VN antibodies in
serum 1422. The finding that one amino acid substitution
allowed FIV19kl to escape from neutralization by the cat
serum collected 22 weeks p.i. indicates that this substitution
affects a dominant VN antibody-inducing determinant
against which the majority of VN antibodies in this serum
are directed during the first months of infection. Another
explanation would be that this substitution influences more
than one VN antibody-inducing epitope. The observation by
Tozzini et al. (42) and Fevereiro et al. (5) that within 4 weeks
after FIV infection, serum antibodies with broad VN activity
can be detected suggests that as in HIV-1 infection of
humans, broadly reactive VN antibodies are formed. It
should, however, be stressed that the VN assays that they
used were carried out with FIV strains adapted to replication
in a continuous fibroblastoid feline kidney cell (CrFK) line,
whereas our VN assays were carried out in primary cat
lymphocytes or thymocytes. Lymphoid cells, which are the
natural target cells for FIV replication in vivo, can readily be
infected with all strains of FIV, whereas only few FIV
strains could be adapted to replication in CrFK cells. The
genetic basis for this adaptation is currently unknown, but
since upon transfection with proviral DNA, CrFK cells may
produce FIV that cannot reinfect CrFK cells, virus entry is
probably the limiting step. Therefore, it may be speculated
that the broad neutralization observed in the assays based on
CrFK cell-adapted FIV strains specifically interferes with
the process underlying this limiting step.
Our future studies to elucidate the structural basis of FIV
neutralization will also be based on the observations made
with FIV19k32. This virus, like FIV19klesc, was not neu-
tralized by serum 1422. Exchange of the NsiI-MstlI fragment
of 19kl for the homologous fragment of 19k32, which con-
tains the HV-5 region, could not confer resistance to 19kl.
Since exchanging the 1,662-bp KpnI fragment between 19kl
and 19k32 resulted in transfer of the neutralization-resistant
phenotype and the envelope proteins of 19kl and 19k32
differ in only six amino acids, two of which are located
within the HV-5 region (Fig. 3), genetic exchange experi-
ments will reveal the exact location of additional regions
involved in escape from virus neutralization.
As in other lentivirus infections, VN antibodies and cyto-
toxic T cells may be expected to play a crucial role in the
pathogenesis of and the protective immunity against FIV
infections. Therefore, detailed analysis of antigenic sites of
FIV involved in the induction of VN antibodies and the
mechanism leading to VN-resistant FIV variants will lead to
a better understanding of lentivirus pathogenesis and help in
the design of effective lentivirus vaccines.
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